Recruitment Status

Not yet recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3237

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Biomarkers, Acute Kidney Injury, Sepsis
Interventions: Not listed
Lead sponsor: Nutromics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California • Stanford, California + 2 more

Conditions: Glaucoma
Interventions: Aflibercept Injection, Ahmed Tube Surgery; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Carcinoma, Head and Neck Carcinoma
Interventions: Training and Education, Communication Intervention, Survey Administration, Interview, Electronic Health Record Review; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD), Arterial Inflammation, Heart Disease
Interventions: Eplerenone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Leukemia, Pediatric Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia in Remission, Pediatric Obesity
Interventions: Modified Guided Self-Help Family Intervention, NIH Educational Resources, FitBit Ace, WashU Extended Learning Canvas; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Brain Injuries, Traumatic, Cerebral Hemorrhage, Ischemic Stroke, Delayed Emergence From Anesthesia, Encephalopathy
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Treatment Resistant Depression, Substance Use Disorders
Interventions: Psilocybin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Epigenetic Aging
Interventions: Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 35 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Houston, Texas

Conditions: Chronic Venous Disease, Chronic Venous Insufficiency, CVI, Venous Thrombosis, Thrombosis (Stent Thrombosis), Thrombosis, Venous, Embolism and Thrombosis, Thrombectomy
Interventions: Recanalization and debulking; Device
Lead sponsor: Intervene, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Multiple Sclerosis
Interventions: SPIN exercise-training, Control Condition (WELL); Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammation, Depression Disorder, Mindfulness, Emotional Well-being, Physical Health, Mental Health
Interventions: Mindfulness-based cognitive therapy for perinatal depression, Pregnancy Health Group; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Interventions: WAYPOINT; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Not yet recruiting clinical trials

Filter and sort this status page

Live official records

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial

Reducing Arterial Inflammation Using Eplerenone and Statins in HIV

Weight Gain in Pediatric Leukemia Survivors

Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry

Efficacy of Seated Physical Activity INtervention(SPIN) for Wheelchair Users With Multiple Sclerosis

Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health

Symptom Monitoring and Management Intervention After CAR-T